## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Cornelis Marius TIMMERS et al.

Serial No.: 10/540,336

Int'l Application No.: PCT/EP03/51025 Int'l Filing Date: December 16, 2003

For: TETRAHYDROQUINOLINE DERIVATIVES :

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Docket: 2002.750 US

**Group Art Unit:** 

Examiner:

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as First-Class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

September 20, 2005

Christina Cangelos

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the requirements of 37 CFR §1.56, applicants submit the documents attached hereto. Pursuant to the United States Patent and Trademark Office. OG Notice 05 August 2003, applicants have excluded copies of the two (2) U.S. patent documents. All documents are to be made of record in the above-identified case. A listing of said documents on form PTO-1449 is also attached.

The present Information Disclosure Statement is being filed within three months of entrance into the U.S. National stage; therefore, no filing fee is believed to be required. If a filing fee is required, the Commissioner is hereby authorized to charge applicants' deposit account 01-1350 for the full amount of said fee.

A copy of the International Search Report dated June 14, 2004 is enclosed herewith.

This statement is not intended to represent that no better art exists. Applicants reserve the right to contest the applicability of the documents attached hereto as prior art in the event that any information is discovered which demonstrates that said documents do not qualify as prior art.

Consideration of the present Information Disclosure Statement is respectfully requested. The claimed invention is, however, deemed to represent a patentable departure from the teachings of the prior art.

Respectfully submitted,

F. Aaron Dubberley Attorney for Applicant(s)

Reg. No. 41,001

Akzo Nobel Inc.
Intellectual Property Dept.
7 Livingstone Avenue
Dobbs Ferry, NY 10522-3408
Tel No.: (973) 325-4542

## Serial No. Atty. Docket # INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) 10/540,336 2002.750 US PTO-1449 (modified) **Applicant** Cornelis Marius TIMMERS et al. **Group Art Unit** Int'l Filing Date December 16, 2003 U.S. PATENT DOCUMENTS Filing Issue Name Class Subclass Date Init Document No. Date 514 150 6,200,963 B1 Wrobel et al. 3/13/2001 260 287 2,686,182 8/10/1954 Hopff et al. FOREIGN PATENT DOCUMENTS Publ. Translation Country Subclass Document No. Date Class Ν WO 00/08015 2/17/2000 PCT C07D 405/00 A61K 9/70 EP 0303 306 B1 2/15/1989 European OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) International Search Report, No.: PCT/EP03/51025, 14 June 2004 Ronald L. Atkins et al., "Substituted Coumarins and Azacoumarins. Synthesis and Fluorescent Properties," J. Org. Chem., Vol. 43, No. 10, pages 1975-1980 (1978) Jay V. Johnson et al., "2,4-Diamino-5-benzylpyrimidines and Analogues as Antibacterial Agents. 12.1,2-Dihydroquinolymethyl Analogues with High Activity and Specificity for Bacterial Dihydrofolate Reductase," J. Med. Chem. Vol. 32, pages 1942-1949 (1989) James P. Edwards et al., "5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists: The Effect of D-Ring Substituents," J. Med. Chem. Vol. 41, pages 303-310 (1998) Lawrence G. Hamann et al., "Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydrophyridono[5,6-g]quinolines," J. Med. Chem, Vol. 41, pages 623-639 (1998) Maria-Elena Theoclitou et al, "Novel facile synthesis of 2,2,4 substituted 1,2-dihydroquinolines via a modified Skraup reaction," Tetrahedron Letters 43, pages 3907-3910 (2002) Jennifer H. Dorrington et al., "Effects of FSH on Gonadal Functions," Recent Progress In Hormone Research, Vo. 35, pages 301-342 (1979) "Gonadotropin Therapy: New Trends and Insights," Int J. Fertil, Vol. 33, pages 85-97 (1988) Richard M. Sharpe "Intratesticular Control of Steroidogenesis," Clinical Endocrinology, Vol. 33, pages 787-807 (1990) Jane H. Morse et al., "Heterogeneity of Proteins in Commercial Preparations of Human Chorionic Gonadotropin (hCG) Demonstrated by Western Blotting," American Journal of Reproductive Immunology And Microbiology, Vol. 17 pages 134-140 (1988) Wiebe Olijive et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," Molecular Human Reproduction, Vol. 2, No. 5, pages 371-382 (1996) Daniel Navot et al., "The Use of Follicle-Stimulating Hormone for Controlled Ovarian Hyperstimulation in in Vitro Fertilization," Vol. 4, pages 3-13 (1988) 'Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH," The Lancet, Vol. 339, pages 1170-1171 (1992) **EXAMINER** DATE CONSIDERED